Antimineralocorticoids offer no benefit in heart attack patients without heart failure

August 30, 2015, European Society of Cardiology

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

The Hot Line findings, reported at ESC Congress 2015, "do not warrant the extension of MRA use" to such , said the study's principal investigator Gilles Montalescot, MD, PhD.

MRAs, also known as aldosterone antagonists, inhibit sodium retention and excretion of potassium and magnesium, and therefore "there is an indication for MRA in MI patients with ," explained Professor Montalescot, from the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtri?re, in Paris, France.

"Our results suggest that heart failure is the main factor for the favorable effect of MRAs previously observed in MI patients. In MI patients without heart failure we observed no benefit. We suggest to respect the current indication driven by heart failure."

But there is a silver lining to the ALBATROSS findings, which do suggest "a potential mortality benefit" of MRA treatment among a specific group of patients who have ST-segment elevation myocardial infarction (STEMI), although this result "must be interpreted with great caution," warned Professor Montalescot.

"It is an intriguing, hypothesis-generating finding which needs to be examined further in adequately-sized trials specifically dedicated to STEMI patients," he said.

While the MRAs spironolactone and eplerenone have both been shown to reduce mortality in with , very little is known about this treatment in the absence of heart failure - the more common scenario among patients who are hospitalised for myocardial infarction (MI).

Therefore, ALBATROSS (which stands for Aldosterone Lethal effects Blockade in Acute Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) investigated the effects of prolonged MRA therapy initiated early after the onset of MI in a broad population, 92% of whom presented without heart failure.

The study included 1622 patients randomly assigned to standard therapy alone (n=801) or with the addition of MRA therapy (n=802).

The randomisation took place as early as possible, including in ambulances, to allow for early treatment.Standard therapy included in-hospital medications as well as procedures such as coronary angiography, percutaneous coronary intervention and coronary bypass grafting.

The MRA regimen consisted of an intravenous bolus of potassium canrenoate (200 mg) followed by an initial 25mg of oral spironolactone within 12 to 24 hours, and then daily for 6 months. Spironolactone was not given if either potassium or creatinine concentrations were uncontrolled (> 5* 5 mmol.L-1 and >220 µmol.L-1 respectively).

After a median follow-up of 118 days, the primary outcome - a composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for an implantable defibrillator or new or worsening heart failure at 6-months - occurred at a similar rate in the treatment and control groups (11* 8% and 12* 2% respectively, hazard ratio [HR] 0* 97).

However, for the outcome of mortality alone, MRA reduced the odds of death in the subgroup of STEMI (n=1229, HR 0* 20, 95% CI, 0.06 to 0.70), but not NSTEMI patients.

Caution in interpreting this finding is warranted since the study was not designed to specifically assess STEMI patients, said Professor Montalescot, but he added that a potential benefit of early MR therapy is plausible in STEMI patients, who are "a more homogeneous patient population with more acute and severe myocardial ischemia than NSTEMI".

The ALBATROSS study, which is the largest study of MRA therapy in MI patients without heart failure, also highlights the relative safety of the MRA regimen used. Adverse events were equally distributed between the two study groups and although rates of hyperkalemia (high plasma potassium) were more common in the MRA group than in the control group, they were lower than what has been previously reported, he concluded.

Explore further: Eplerenone reduces primary endpoint in acute myocardial infarction patients

Related Stories

Eplerenone reduces primary endpoint in acute myocardial infarction patients

April 29, 2014
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect,say the ...

Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome

August 30, 2015
Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress today by co-principal investigator ...

Drug may improve outcomes after heart attack

March 12, 2013
The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's ...

Metformin does not improve heart function in patients without diabetes

March 31, 2014
Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favorable effects on ventricular (heart) function, among patients without diabetes who underwent percutaneous ...

Novel stem cell approach promising for heart failure

August 3, 2015
(HealthDay)—A new method for delivering stem cells to damaged heart muscle has shown early promise in treating severe heart failure, researchers report online July 27 in Stem Cells Translational Medicine.

Levosimendan improves event free survival by 50 percent in end-stage heart failure

May 27, 2013
Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a ...

Recommended for you

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...

Mediterranean-style diet may lower women's stroke risk

September 20, 2018
Following a Mediterranean-style diet may reduce stroke risk in women over 40 but not in men—according to new research led by the University of East Anglia.

Inflammation critical for preventing heart attacks and strokes, study reveals

September 19, 2018
Inflammation, long considered a dangerous contributor to atherosclerosis, actually plays an important role in preventing heart attacks and strokes, new research from the University of Virginia School of Medicine reveals.

People who walk just 35 minutes a day may have less severe strokes

September 19, 2018
People who participate in light to moderate physical activity, such as walking at least four hours a week or swimming two to three hours a week, may have less severe strokes than people who are physically inactive, according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.